Quarterly report pursuant to Section 13 or 15(d)

ORGANIZATION AND PLAN OF BUSINESS OPERATIONS (Details)

v3.24.3
ORGANIZATION AND PLAN OF BUSINESS OPERATIONS (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Nov. 04, 2024
USD ($)
Jun. 26, 2024
USD ($)
Dec. 27, 2023
USD ($)
Jan. 26, 2023
USD ($)
shares
Sep. 30, 2024
USD ($)
shares
Sep. 30, 2024
USD ($)
item
shares
Sep. 30, 2023
USD ($)
Jul. 09, 2024
USD ($)
Jul. 08, 2024
USD ($)
Dec. 31, 2023
USD ($)
ORGANIZATION AND PLAN OF BUSINESS OPERATIONS                    
Number of branded drugs in product portfolio | item           7        
Number of authorized generic prescription drugs | item           2        
Cash and cash equivalents         $ 22,461 $ 22,461       $ 27,439
Proceeds from term-loan, net of issuance costs           4,950        
Remaining amount drawn under the credit facility             $ 28,000      
Stock issued value         $ 194 1,678        
Proceeds from issuance of common stock           $ 1,678        
Common Stock                    
ORGANIZATION AND PLAN OF BUSINESS OPERATIONS                    
Stock issued value       $ 150,000            
Stock issued (in shares) | shares       4,900,000 35,275 325,019        
Proceeds from issuance of common stock           $ 1,700        
Common Stock | Employee severance obligation                    
ORGANIZATION AND PLAN OF BUSINESS OPERATIONS                    
Number of shares available for issuance | shares         3,826,278 3,826,278        
Subsequent Event | Emrosi Agreement                    
ORGANIZATION AND PLAN OF BUSINESS OPERATIONS                    
Outstanding borrowings $ 5,000                  
Amount received from FDA under the license, collaboration, and assignment agreement $ 15,000                  
Period of milestone obligation to be paid off from the date of approval received 30 days                  
Term loan | SWK Funding LLC                    
ORGANIZATION AND PLAN OF BUSINESS OPERATIONS                    
Maximum borrowing capacity     $ 20,000         $ 25,000 $ 20,000  
Proceeds from term-loan, net of issuance costs     $ 15,000              
Remaining amount drawn under the credit facility   $ 5,000                
Spread on variable rate     7.75%              
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]     us-gaap:SecuredOvernightFinancingRateSofrMember              
Floor rate     5.00%              
Principal amount of funded term loans     7.50%   7.50% 7.50%        
Additional borrowing capacity               $ 5,000